Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Immuneering Corporation (IMRX : NSDQ)
 
 • Company Description   
Immuneering Corporation is a biopharmaceutical company advancing a pipeline of oncology and neuroscience product candidates. The company's product candidate includes IMM-1-104. Immuneering Corporation is based in CAMBRIDGE, Mass.

Number of Employees: 64

 
 • Price / Volume Information   
Yesterday's Closing Price: $4.37 Daily Weekly Monthly
20 Day Moving Average: 112,964 shares
Shares Outstanding: 26.39 (millions)
Market Capitalization: $115.30 (millions)
Beta:
52 Week High: $33.99
52 Week Low: $4.11
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -25.81% -18.76%
12 Week -44.33% -37.44%
Year To Date -72.97% -66.98%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
245 MAIN STREET SECOND FLOOR
-
CAMBRIDGE,MA 02142
USA
ph: 617-500-8080
fax: -
susan@sanoonan.com http://www.immuneering.com
 
 • General Corporate Information   
Officers
Benjamin J. Zeskind, Ph.D. - Chief Executive Officer and President
Biren Amin - Chief Financial Officer
Ann E. Berman - Director
Robert J. Carpenter - Director
Peter Feinberg - Director

Peer Information
Immuneering Corporation (CORR.)
Immuneering Corporation (RSPI)
Immuneering Corporation (CGXP)
Immuneering Corporation (BGEN)
Immuneering Corporation (GTBP)
Immuneering Corporation (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45254E107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 09/08/22
Share - Related Items
Shares Outstanding: 26.39
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $115.30 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.51 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.10 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 09/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.80
Price/Cash Flow: -
Price / Sales: 76.06
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -16.67%
Sales Growth
vs. Year Ago Period: -75.40%
vs. Previous Quarter: -3.16%
ROE
03/31/22 - -38.00
12/31/21 - -48.06
09/30/21 - -
ROA
03/31/22 - -29.99
12/31/21 - -34.95
09/30/21 - -
Current Ratio
03/31/22 - 37.98
12/31/21 - 27.04
09/30/21 - 29.11
Quick Ratio
03/31/22 - 37.98
12/31/21 - 27.04
09/30/21 - 29.11
Operating Margin
03/31/22 - -2,651.85
12/31/21 - -1,612.31
09/30/21 - -
Net Margin
03/31/22 - -2,651.85
12/31/21 - -1,612.31
09/30/21 - -
Pre-Tax Margin
03/31/22 - -2,672.10
12/31/21 - -1,627.07
09/30/21 - -
Book Value
03/31/22 - 5.46
12/31/21 - 6.01
09/30/21 - 6.10
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©